Tsfg LLC Acquires 34 Shares of Eli Lilly and Company (NYSE:LLY)

Tsfg LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 4.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 786 shares of the company’s stock after acquiring an additional 34 shares during the quarter. Tsfg LLC’s holdings in Eli Lilly and Company were worth $612,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. DeDora Capital Inc. increased its stake in shares of Eli Lilly and Company by 21.1% in the first quarter. DeDora Capital Inc. now owns 2,152 shares of the company’s stock valued at $1,674,000 after buying an additional 375 shares in the last quarter. Ameliora Wealth Management Ltd. increased its stake in shares of Eli Lilly and Company by 52.1% in the first quarter. Ameliora Wealth Management Ltd. now owns 2,325 shares of the company’s stock valued at $1,809,000 after buying an additional 796 shares in the last quarter. Register Financial Advisors LLC increased its stake in shares of Eli Lilly and Company by 6.1% in the first quarter. Register Financial Advisors LLC now owns 1,067 shares of the company’s stock valued at $830,000 after buying an additional 61 shares in the last quarter. Capital Asset Advisory Services LLC increased its stake in shares of Eli Lilly and Company by 3.7% in the first quarter. Capital Asset Advisory Services LLC now owns 5,518 shares of the company’s stock valued at $4,327,000 after buying an additional 198 shares in the last quarter. Finally, Indiana Trust & Investment Management CO increased its stake in shares of Eli Lilly and Company by 5.7% in the first quarter. Indiana Trust & Investment Management CO now owns 16,380 shares of the company’s stock valued at $12,743,000 after buying an additional 880 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Down 0.3 %

NYSE LLY opened at $905.87 on Friday. The stock has a market capitalization of $860.95 billion, a price-to-earnings ratio of 133.41, a PEG ratio of 1.98 and a beta of 0.36. The stock’s 50 day moving average price is $814.40 and its two-hundred day moving average price is $738.79. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a 52 week low of $434.34 and a 52 week high of $915.54.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.62 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 17,229 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $902.38, for a total transaction of $15,547,105.02. Following the transaction, the insider now owns 97,556,910 shares of the company’s stock, valued at approximately $88,033,404,445.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 17,229 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $902.38, for a total value of $15,547,105.02. Following the sale, the insider now owns 97,556,910 shares of the company’s stock, valued at $88,033,404,445.80. The disclosure for this sale can be found here. Insiders have sold 789,704 shares of company stock valued at $672,385,964 in the last 90 days. 0.13% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Argus lifted their price objective on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, Bank of America restated a “buy” rating and set a $1,000.00 target price on shares of Eli Lilly and Company in a report on Monday, June 24th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $812.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.